<< New study of diabetes patients across five European countries launched by GfK Healthcare | Boston Scientific extends its sympathies to Senator Kennedy's family >>

Novabay Pharmaceuticals closes its previously announced registered direct offering of common stocks and warrants

Published on August 27, 2009 at 6:14 AM · No Comments

NovaBay® Pharmaceuticals, Inc. (NYSE Amex: NBY) announced today that it has closed its previously announced registered direct offering of 1,225,000 units, with each unit consisting of (i) one share of the NovaBay common stock, par value $0.01 per share, and (ii) one warrant to purchase one share of NovaBay common stock. The purchase price for each unit was $2.00. Each warrant has an exercise price of $2.75, which will be exercisable 180 days after issuance and will expire five years from the date of issuance. The units will not be issued or certificated and neither the units nor warrants will trade on any exchange or be listed for quotation on any market. Maxim Group LLC served as placement agent for the offering.

The units were offered by NovaBay pursuant to a registration statement previously filed and declared effective by the Securities and Exchange Commission.

SOURCE: NovaBay Pharmaceuticals

Posted in:

Tags: , , , ,

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading